Table 3.
Multivariable analysis of association of AKI by patient characteristics and ICI regimens
| Parameter | Category |
AKI Definition 1a |
AKI Definition 1b |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HazardRatio | 95% ConfidenceInterval | P-value for Comparison with Reference | P-Value for Overall Effect | HazardRatio | 95% ConfidenceInterval | P-value for Comparison with Reference | P-Value for Overall Effect | ||||||
| Drug (ref = ’ pembrolizumab’) | Ipilimumab | 3.281 | 1.213 | 8.873 | 0.0192 | <0.0001 | 4.096 | 1.415 | 11.856 | 0.0093 | <0.0001 | ||
| Ipilimumab/nivolumab | 3.725 | 1.144 | 12.134 | 0.0291 | 5.101 | 1.554 | 16.745 | 0.0072 | |||||
| Ipilimumab/pembrolizumab | 6.305 | 2.436 | 16.318 | 0.0001 | 9.041 | 3.246 | 25.177 | <0.0001 | |||||
| Nivolumab | 1.022 | 0.270 | 3.872 | 0.9749 | 2.693 | 0.824 | 8.806 | 0.1012 | |||||
| Age | Per year increase | 0.981 | 0.966 | 0.996 | 0.0152 | 0.0152 | |||||||
| Race (ref = ’White’) | Asian | 4.182 | 1.090 | 16.043 | 0.0370 | 0.0370 | 4.387 | 1.519 | 12.664 | 0.0063 | 0.0063 | ||
| PPI | Yes vs No | 2.387 | 1.328 | 4.291 | 0.0036 | 0.0036 | 2.355 | 1.393 | 3.983 | 0.0014 | 0.0014 | ||